Eli Lilly’s experimental obesity pill, orforglipron, is showing major promise in late-stage trials — helping users lose an average of 10.5% of their body weight, or nearly 23 pounds, over 16 months.
Unlike other popular GLP-1 medications, which are mostly injectables, orforglipron is a once-daily oral pill with no food or water restrictions — making it one of the most convenient options under development.
In a phase 3 clinical trial involving over 1,600 overweight adults with type 2 diabetes, participants were randomly assigned to receive one of three doses of orforglipron (6 mg, 12 mg, or 36 mg) or a placebo. After 72 weeks, results showed:
-
36 mg dose: 10.5% average weight loss
-
12 mg dose: 7.8% average weight loss
-
6 mg dose: 5.5% average weight loss
-
Placebo: 2.2% average weight loss (~5 pounds)
Beyond weight loss, orforglipron also led to significant reductions in hemoglobin A1C (a key diabetes marker), along with improvements in blood pressure, bad cholesterol (non-HDL), and triglycerides — all critical for heart and metabolic health.
Side effects were consistent with other GLP-1 drugs and included nausea, diarrhea, constipation, indigestion, and vomiting, mostly mild to moderate. However, about 10.6% of users on the highest dose discontinued due to side effects, compared to 4.6% in the placebo group.
GLP-1 drugs work by mimicking a natural hormone that helps regulate appetite, making people feel full longer and reducing food cravings. But quitting these medications often leads to rapid weight regain, as hunger signals and metabolism return to pre-treatment levels.
Currently, most GLP-1 drugs, including Ozempic and Wegovy, are injectable. Rybelsus is the only approved oral GLP-1 drug, used for diabetes. However, Eli Lilly’s orforglipron could become the first oral GLP-1 approved specifically for obesity treatment — a major step in making weight-loss medication more accessible worldwide.
Lilly plans to submit the full trial data to U.S. regulators by the end of the year, potentially opening a new chapter in obesity care with needle-free treatment.
Leave a reaction
